15

25

Claims

- 1. Use of the *cis-9,trans-11* isomer of conjugated linoleic acid (CLA) for making a medicament for fighting inflammatory diseases.
 - 2. Use according to claim 1, **characterised in** that said medicament acts against the hypersensitivity of the bronchia.
- 3. Use according to claim 1, **characterised in** that said medicament acts against respiratory diseases, particularly against asthma.
 - 4. Use according to claim 1, **characterised in** that said medicament acts against rheumatic diseases, particularly rheumatic arthritis.
 - 5. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acid for the inhibition of the proliferation of human or animal cells, particularly cells of the immune systems involved in immune response.
- 6. Use of the *cis-9,trans-11* isomer of conjugated linoleic acid for the support of apoptosis of eosinophilic granulocytes.
 - 7. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acid for the inhibition of specific cytokine expression.
 - 8. Use according to at least one of claims 1 to 7, **characterised in** that a technical grade CLA is used, comprising said *cis*-9,*trans*-11 isomer in amounts of at least 30 % b.w. calculated on the total CLA content.
- 9. Use according to at least one of claims 1 to 8, **characterised in** that a technical grade CLA is used whose acyl moiety comprises at most 30 % b.w. *trans*-10,*cis*-12 isomers and in total less than 1 % b.w. 8,10-, 11,13 and *trans*, trans isomers calculated on the total CLA content.
- 10. Use according to at least one of claims 1 to 9, **characterised in** that said CLA or, as an alternative, said medicament is applied sub-cutaneously, intramuscularly, per inhalation, per infusionem, topically or orally.

5

- 11. Use of the *cis-9,trans-11* isomer of conjugated linoleic acids as a nutrition, functional food or dietary supplement agent.
- 12. Use according to at least one of claims 1 to 11, characterised in that said CLA is applied in amounts of from 0.05 to 5 g/day.